{"protocolSection":{"identificationModule":{"nctId":"NCT06491563","orgStudyIdInfo":{"id":"BRII-179-835-002"},"organization":{"fullName":"Brii Biosciences Limited","class":"INDUSTRY"},"briefTitle":"Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)","officialTitle":"A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)"},"statusModule":{"statusVerifiedDate":"2024-12","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-28","studyFirstSubmitQcDate":"2024-07-04","studyFirstPostDateStruct":{"date":"2024-07-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-12-26","lastUpdatePostDateStruct":{"date":"2024-12-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Brii Biosciences Limited","class":"INDUSTRY"},"collaborators":[{"name":"Vir Biotechnology, Inc.","class":"INDUSTRY"}]},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy."},"conditionsModule":{"conditions":["For Treatment of Chronic Hepatitis B Virus Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":150,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα","type":"EXPERIMENTAL","description":"Participants will receive BRII-179 of a longer dose interval, followed by BRII-835 and PEG-IFNα combination therapy.","interventionNames":["Biological: BRII-179","Drug: BRII-835 (VIR-2218)","Biological: PEG-IFNα"]},{"label":"BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα","type":"EXPERIMENTAL","description":"Participants will receive BRII-179 of a shorter dose interval, followed by BRII-835 and PEG-IFNα combination therapy.","interventionNames":["Biological: BRII-179","Drug: BRII-835 (VIR-2218)","Biological: PEG-IFNα"]}],"interventions":[{"type":"BIOLOGICAL","name":"BRII-179","description":"BRII-179 will be given via intramuscular injection","armGroupLabels":["BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα","BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα"]},{"type":"DRUG","name":"BRII-835 (VIR-2218)","description":"BRII-835 will be given via subcutaneous injection","armGroupLabels":["BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα","BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα"],"otherNames":["elebsiran"]},{"type":"BIOLOGICAL","name":"PEG-IFNα","description":"PEG-IFNα will be given via subcutaneous injection","armGroupLabels":["BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα","BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα"],"otherNames":["Pegylated interferon alfa"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepoint","timeFrame":"24 weeks post end of treatment"}],"secondaryOutcomes":[{"measure":"Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepoint (in participants with lower baseline HBsAg levels)","timeFrame":"24 weeks post end of treatment"},{"measure":"Percentage of participants with treatment-emergent adverse events (TEAEs)","timeFrame":"24 weeks post NRTI discontinuation"},{"measure":"Percentage of participants with serious adverse events (SAEs)","timeFrame":"24 weeks post NRTI discontinuation"},{"measure":"Percentage of participants with abnormalities in hematology, chemistry, and/or coagulation parameters","timeFrame":"24 weeks post NRTI discontinuation"},{"measure":"Appearance of anti-HBs at any timepoint","timeFrame":"24 weeks post NRTI discontinuation"},{"measure":"Titers of anti-HBs at any timepoint","timeFrame":"24 weeks post NRTI discontinuation"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 1\\. Male or female aged 18-60 years.\n* 2\\. Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2.\n* 3\\. Chronic HBV infection for ≥ 6 months.\n* 4\\. On NRTI therapy for ≥ 6 months.\n\nExclusion Criteria:\n\n* 1\\. Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation.\n* 2\\. Significant liver fibrosis or cirrhosis.\n* 3\\. History or evidence of drug or alcohol abuse.\n* 4\\. History of intolerance to SC or IM injection.\n* 5\\. History of chronic liver disease from any cause other than chronic HBV infection.\n* 6\\. History of hepatic decompensation.\n* 7\\. Contraindications to the use of PEG-IFNα.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Xiaofei Chen","affiliation":"Brii Biosciences Limited","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Investigative Site 86004","city":"Beijing","state":"Beijing Municipality","zip":"100000","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Investigative Site 86009","city":"Beijing","state":"Beijing Municipality","zip":"100000","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Investigative Site 86015","city":"Xiamen","state":"Fujian","zip":"361000","country":"China","geoPoint":{"lat":24.47979,"lon":118.08187}},{"facility":"Investigative Site 86012","city":"Foshan","state":"Guangdong","zip":"528000","country":"China","geoPoint":{"lat":23.02677,"lon":113.13148}},{"facility":"Investigative Site 86001","city":"Guangzhou","state":"Guangdong","zip":"510000","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Investigative Site 86013","city":"Guangzhou","state":"Guangdong","zip":"510000","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Investigative Site 86002","city":"Shenzhen","state":"Guangdong","zip":"518000","country":"China","geoPoint":{"lat":22.54554,"lon":114.0683}},{"facility":"Investigative Site 86003","city":"Shanghai","state":"Shanghai Municipality","zip":"200000","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Investigative Site 86008","city":"Shanghai","state":"Shanghai Municipality","zip":"200000","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Investigative Site 86007","city":"Chengdu","state":"Sichuan","zip":"610000","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Investigative Site 86011","city":"Chengdu","state":"Sichuan","zip":"610000","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Investigative Site 86005","city":"Hangzhou","state":"Zhejiang","zip":"310000","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false}